Ambalal Sarabhai Enterprises
AMBALALSA NSE
Ambalal Sarabhai Enterprises
HealthcareNSE: AMBALALSA BSE: 500009 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹314 Cr
Volatility
Moderate
P/E Ratio
74.69
EBITDA
₹26.90 Cr
Return on Equity
11.24%
Debt to Equity
0.18
Book Value
₹20.66
52W High
₹49.98
52W Low
₹30.15
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
6- Stock is trading at 5.20 times its book value
- Promoter holding is low: 31.4%
- Tax rate seems low
- Company has a low return on equity of 12.1% over last 3 years.
- Earnings include an other income of Rs.9.11 Cr.
- Working capital days have increased from 267 days to 1,379 days
Growth Rate
Revenue Growth
4.72% higher than
3Y
Net Income Growth
263% higher than
3Y
Cash Flow Change
176% higher than
3Y
ROE
219% higher than
3Y
ROCE
105% higher than
3Y
EBITDA Margin (Avg.)
32.09% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.7 | 0.8 | 0.33 | 0.99 | 1.14 | 0 | 1.17 | 1.73 | 1.64 | 0.79 | 0 | 1.52 | 0.54 |
| Expenses | 4.84 | 2.13 | 1.96 | 1.64 | 2.41 | 1.8 | 3.74 | 3.43 | 2.83 | 2.43 | 0.94 | 2.88 | 1.76 |
| Operating Profit | -3.14 | -1.33 | -1.63 | -0.65 | -1.27 | -1.8 | -2.57 | -1.7 | -1.19 | -1.64 | -0.94 | -1.36 | -1.22 |
| OPM % | -184.71% | -166.25% | -493.94% | -65.66% | -111.4% | — | -219.66% | -98.27% | -72.56% | -207.59% | — | -89.47% | -225.93% |
| Other Income | 1.18 | 1.96 | 1.33 | 3.41 | 1.88 | 6.37 | 10.81 | -3.21 | 8.17 | 1.36 | 2.89 | 3.16 | 1.7 |
| Interest | 0.03 | 0.04 | 0.06 | 0.07 | 0.09 | 0.09 | 0.1 | 0.05 | 0.07 | 0.08 | 0.09 | 0.17 | 0.17 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| PBT | -2.02 | 0.56 | -0.39 | 2.66 | 0.49 | 4.45 | 8.12 | -4.98 | 6.89 | -0.38 | 1.84 | 1.61 | 0.29 |
| Tax % | 0% | 0% | 69.23% | -76.32% | 6.12% | 3.15% | -3.82% | -0.4% | 0% | 0% | -0.54% | -64.6% | 89.66% |
| Net Profit | -2.02 | 0.56 | -0.65 | 4.7 | 0.46 | 4.31 | 8.43 | -4.96 | 6.88 | -0.38 | 1.84 | 2.65 | 0.03 |
| EPS in Rs | -0.26 | 0.07 | -0.08 | 0.61 | 0.06 | 0.56 | 1.1 | -0.65 | 0.9 | -0.05 | 0.24 | 0.35 | 0 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.25 | 6.98 | 1.51 | 0.92 | 0 | 0 | 0 | 0.13 | 3.71 | 3.81 | 4.04 | 3.94 | 2.85 |
| Expenses | 27.3 | 28.62 | 14.47 | 21.76 | 8.86 | 7.86 | 11.69 | 5.71 | 8.87 | 8.61 | 11.37 | 9.06 | 8.01 |
| Operating Profit | -12.05 | -21.64 | -12.96 | -20.84 | -8.86 | -7.86 | -11.69 | -5.58 | -5.16 | -4.8 | -7.33 | -5.12 | -5.16 |
| OPM % | -79.02% | -310.03% | -858.28% | -2265.22% | — | — | — | -4292.31% | -139.08% | -125.98% | -181.44% | -129.95% | -181.05% |
| Other Income | 14.17 | 95.94 | -0.63 | 24.49 | 6.46 | 24.61 | 3.16 | 9.47 | 9.75 | 7.89 | 15.85 | 15.57 | 9.11 |
| Interest | 7.91 | 1.99 | 2.62 | 1.05 | 0.62 | 0.46 | 0.56 | 0.25 | 0.11 | 2.16 | 0.34 | 0.41 | 0.51 |
| Depreciation | 3.36 | 14.62 | 2.45 | 0.42 | 0.4 | 0.39 | 0.38 | 0.19 | 0.15 | 0.12 | 0.1 | 0.09 | 0.08 |
| PBT | -9.15 | 57.69 | -18.66 | 2.18 | -3.42 | 15.9 | -9.47 | 3.45 | 4.33 | 0.81 | 8.08 | 9.95 | 3.36 |
| Tax % | 0% | 20.8% | 10.18% | 166.06% | 13.45% | 2.2% | -0.84% | 14.49% | 5.31% | -217.28% | -1.98% | -10.45% | — |
| Net Profit | -9.15 | 45.68 | -20.57 | -1.44 | -3.88 | 15.55 | -9.39 | 2.96 | 4.11 | 2.58 | 8.24 | 10.99 | 4.14 |
| EPS in Rs | -1.19 | 5.96 | -2.68 | -0.19 | -0.51 | 2.03 | -1.23 | 0.39 | 0.54 | 0.34 | 1.08 | 1.43 | 0.54 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 |
| Reserves | -73.49 | -27.8 | -46.41 | -47.98 | -51.85 | -36.39 | -45.85 | -42.93 | -38.79 | -36.34 | -28.14 | -17.15 |
| Borrowings | 30.1 | 29.54 | 22.13 | 11.07 | 11.07 | 11 | 11.14 | 9.77 | 11.49 | 10.03 | 7.66 | 11 |
| Other Liabilities | 103 | 65.13 | 63.81 | 91.28 | 103 | 73.35 | 58.14 | 39.53 | 30.42 | 30.96 | 26.77 | 15.31 |
| Total Liabilities | 136 | 144 | 116 | 131 | 139 | 125 | 100 | 83 | 79.75 | 81.28 | 82.92 | 85.79 |
| Fixed Assets | 42.66 | 20.6 | 16.43 | 14.98 | 14.65 | 14.48 | 13.97 | 13 | 12.86 | 12.84 | 12.22 | 12.13 |
| CWIP | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 56.29 | 82.91 | 76.19 | 55.88 | 55.97 | 56.43 | 26.58 | 25.54 | 25.54 | 25.39 | 25.34 | 25.34 |
| Other Assets | 37.43 | 39.99 | 23.54 | 60.14 | 68.01 | 53.68 | 59.51 | 44.46 | 41.35 | 43.05 | 45.36 | 48.32 |
| Total Assets | 136 | 144 | 116 | 131 | 139 | 125 | 100 | 83 | 79.75 | 81.28 | 82.92 | 85.79 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -12.05 | -69.37 | -3.67 | -12.66 | -3.27 | -4.53 | -10.42 | -7.79 | 1.52 | -3.82 | -4.08 | -0.26 |
| Investing | 12.7 | 75.22 | 8.64 | 26.14 | 2.37 | 4.92 | 15.76 | 20.77 | 0.61 | 3.48 | 6.35 | -3.02 |
| Financing | -0.75 | -2.56 | -8.14 | -12.15 | -0.44 | -0.42 | -0.32 | -16.46 | -3.76 | 0.3 | -2.31 | 3.4 |
| Net Cash Flow | -0.1 | 3.3 | -3.17 | 1.33 | -1.33 | -0.03 | 5.02 | -3.47 | -1.63 | -0.04 | -0.04 | 0.11 |
| Free Cash Flow | -0.49 | 31.11 | -3.04 | 1.72 | -3.33 | -4.5 | 0.66 | 11.47 | 1.58 | -3.91 | 1.11 | -0.27 |
| CFO/OP | 71 | 304 | 27 | -24 | -11 | 51 | 85 | 128 | -45 | 65 | 47 | 61 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 37.34 | 1.57 | 0 | 0 | — | — | — | 421 | 29.51 | 37.36 | 37.04 | 38.91 |
| Inventory Days | 76.36 | 22.52 | 47.93 | 56.64 | — | — | — | 0 | 2.01 | 0 | 0 | 6.62 |
| Days Payable | 321 | 729 | 3,974 | 13,253 | — | — | — | — | 1,612 | — | — | 712 |
| Cash Conversion Cycle | -207 | -705 | -3,927 | -13,197 | — | — | — | 421 | -1,580 | 37.36 | 37.04 | -667 |
| Working Capital Days | -2,355 | -3,036 | -16,106 | -23,785 | — | — | — | -30,660 | -1,038 | -687 | 109 | 1,379 |
| ROCE % | -34.09% | -59.62% | -12.82% | -21.98% | -7.41% | 36.9% | -4.27% | 9.93% | 11.12% | 5.96% | 6.01% | 16.36% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ambalal Sarabhai Enterprises insights
40 extracted metrics + investor summaries across FY15–FY26.
Documents
1
Clarification Sought from Ambalal Sarabhai Enterprises Ltd
5 Aug - Exchange has sought clarification from Ambalal Sarabhai Enterprises Ltd on August 5, 2026 with reference to significant movement in price, in order to ensure that … 5 Aug - Exchange has sought clarification from Ambalal Sarabhai Enterprises Ltd on August 5, 2026 with reference to significant movement in price, in order to ensure that …
2
Intimation Regarding Change In Branch Address Of Registrar & Share Transfer Agent (MCS Share Transfer Agent Limited)
24 Apr - RTA MCS Share Transfer Agent’s branch shifts from Vadodara to Mumbai. 24 Apr - RTA MCS Share Transfer Agent’s branch shifts from Vadodara to Mumbai.
3
Intimation Regarding Change In Branch Address Of Registrar & Share Transfer Agent (MCS Share Transfer Agent Limited)
10h - RTA MCS Share Transfer Agent’s branch shifts from Vadodara to Mumbai. 10h - RTA MCS Share Transfer Agent’s branch shifts from Vadodara to Mumbai.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
2d - Company says it is not a Large Corporate for FY ended March 31, 2026. 2d - Company says it is not a Large Corporate for FY ended March 31, 2026.
5
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
2d - Annual disclosure for FY 2025-26 filed; no incremental borrowing or penalty applicable. 2d - Annual disclosure for FY 2025-26 filed; no incremental borrowing or penalty applicable.
Frequently Asked Questions about Ambalal Sarabhai Enterprises
What does Ambalal Sarabhai Enterprises Ltd do?
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
Where is Ambalal Sarabhai Enterprises Ltd (500009) listed?
Ambalal Sarabhai Enterprises Ltd trades as AMBALALSA on the NSE and under code 500009 on the BSE.
Which sector does Ambalal Sarabhai Enterprises Ltd belong to?
Ambalal Sarabhai Enterprises Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd has a market capitalisation of ₹314.12 Cr, which places it in the Small Cap band.
What is the PE ratio of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd trades at a PE ratio of 74.69, against a book value of ₹20.66 per share.
What is the 52-week high and low of Ambalal Sarabhai Enterprises Ltd?
Over the last 52 weeks Ambalal Sarabhai Enterprises Ltd has traded between ₹30.15 and ₹49.98.
What is the Return on Equity (ROE) of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd reported a return on equity of 11.24%. Its debt-to-equity ratio is 0.18.
Company Information
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/500009.md for Ambalal Sarabhai Enterprises Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.